Pfizer

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Pfizer 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PFE

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. 

CEO
Albert Bourla
CEOAlbert Bourla
Employees
75,000
Employees75,000
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
1849
Founded1849
Employees
75,000
Employees75,000

PFE Key Statistics

Market cap
146.48B
Market cap146.48B
Price-Earnings ratio
19.43
Price-Earnings ratio19.43
Dividend yield
6.79%
Dividend yield6.79%
Average volume
31.79M
Average volume31.79M
High today
$26.01
High today$26.01
Low today
$25.50
Low today$25.50
Open price
$25.71
Open price$25.71
Volume
30.93M
Volume30.93M
52 Week high
$28.75
52 Week high$28.75
52 Week low
$23.08
52 Week low$23.08

Stock Snapshot

As of today, Pfizer(PFE) shares are valued at $25.70. The company's market cap stands at 146.48B, with a P/E ratio of 19.43 and a dividend yield of 6.8%.

On 2026-06-04, Pfizer(PFE) stock moved within a range of $25.50 to $26.01. With shares now at $25.70, the stock is trading +0.8% above its intraday low and -1.2% below the session's peak.

Trading activity shows a volume of 30.93M, compared to an average daily volume of 31.79M.

Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $28.75 and a low of $23.08.

Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $28.75 and a low of $23.08.

PFE News

TipRanks 5h
Pfizer Expands Oncology Pipeline With New PF-08634404 Combo Trial in Advanced Lung Cancer

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings a...

TipRanks 5h
Pfizer and Astellas Advance New Bladder Cancer Combo in Early Clinical Trial

Astellas Pharma (ALPMF), Pfizer Inc (PFE) announced an update on their ongoing clinical study. Unlock trusted, data-backed investing tools with TipRanks Premiu...

TipRanks 5h
Pfizer’s New Lung Cancer Study Signals Fresh Oncology Upside for PFE Investors

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings a...

Analyst ratings

55%

of 29 ratings
Buy
34.5%
Hold
55.2%
Sell
10.3%

More PFE News

Nasdaq 15h
Better High-Yield Dividend Stock to Buy: Bristol Myers Squibb or Pfizer?

Key Points Pfizer has a higher forward dividend yield than Bristol Myers Squibb, but the latter beats the former in most other criteria. Bristol Myers Squibb...

Better High-Yield Dividend Stock to Buy: Bristol Myers Squibb or Pfizer?
TipRanks 1d
Pfizer’s Bevacizumab Biosimilar Safety Study in Japan Reaches Completion: What Investors Should Watch

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings a...

TipRanks 1d
Pfizer’s ODEN Study Update: Real-World Data on Tofacitinib in Ulcerative Colitis

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings a...

24/7 Wall St. 1d
Pfizer vs Merck: Chasing High Yield vs Higher Returns

Pfizer vs Merck: Chasing High Yield vs Higher Returns By Vandita Jadeja Published Jun 3, 10:06AM EDT Quick Read PFE yields 6.58% at a forward P/E of 9, while...

Pfizer vs Merck: Chasing High Yield vs Higher Returns
The Motley Fool 2d
Bristol Myers vs. Pfizer: Which High‑Yield Dividend Stock Wins Now?

Over the past few years, Bristol Myers Squibb (BMY 1.09%) and Pfizer (PFE 0.29%), have underperformed broader equities. However, throughout it all, they have ma...

Bristol Myers vs. Pfizer: Which High‑Yield Dividend Stock Wins Now?
24/7 Wall St. 2d
Why Pfizer’s Current Price May Be Too Cheap to Ignore

Why Pfizer’s Current Price May Be Too Cheap to Ignore By Vandita Jadeja Published Jun 2, 10:03AM EDT Quick Read Pfizer (PFE) trades at $26.18 with a 24/7 Wall...

Why Pfizer’s Current Price May Be Too Cheap to Ignore
Simply Wall St 2d
Pfizer’s ASCO 2026 Cancer Results Test Oncology Focus And Valuation Story

Pfizer reported new seven-year data from the Phase 3 CROWN trial at ASCO 2026, highlighting LORBRENA for untreated ALK-positive advanced non small cell lung can...

Pfizer’s ASCO 2026 Cancer Results Test Oncology Focus And Valuation Story

People also own

Based on the portfolios of people who own PFE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.